Pre-treatment with Idelalisib markedly reduces Rituximab infusion-related reactions and infusion interruptions in patients with CLL

被引：0

作者：

Hallek, M. ^{[1
]}

Hillmen, P. ^{[2
]}

Furman, R. R. ^{[3
]}

Coutre, S. E. ^{[4
]}

Sharman, J. P. ^{[5
]}

Pagel, J. M. ^{[6
]}

Barrientos, J. C. ^{[7
]}

Zelenetz, A. D. ^{[8
]}

Kipps, T. J. ^{[9
]}

Flinn, I. W. ^{[10
]}

Ghia, P. ^{[11
]}

Eradat, H. ^{[12
]}

Erwin, T. ^{[13
]}

Lamanna, N. ^{[14
]}

Coiffier, B. ^{[15
]}

Pettitt, A. R. ^{[16
]}

O'Brien, S. M. ^{[17
]}

Cheson, B. D. ^{[18
]}

Ruppert, S. ^{[19
]}

Kroenig, H. ^{[19
]}

Schuster, A. ^{[19
]}

机构：

[1] Univ Cologne, Innere Med Klin 3, D-50924 Cologne, Germany

[2] Univ Leeds, Leeds, W Yorkshire, England

[3] Weill Cornell Med Coll, New York, NY USA

[4] Stanford Univ, Sch Med, Stanford Canc Ctr, Stanford, CA 94305 USA

[5] US Oncol Res, Springfield, OR USA

[6] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA

[7] Hofstra North Shore LIJ Sch Med, New Hyde Pk, NY USA

[8] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[9] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA

[10] Sarah Cannon Res Inst, Nashville, TN USA

[11] Univ Vita Salute San Raffaele, Ist Sci San Raffaele, Milan, Italy

[12] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[13] Florida Canc Specialists, Englewood, CO USA

[14] Columbia Univ, Med Ctr, New York, NY USA

[15] Lyon Sud Univ Hosp, Lyon, France

[16] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England

[17] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[18] Georgetown Univ Hosp, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA

[19] Gilead Sci GmbH, Martinsried, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2014年 / 37卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P191

引用

页码：52 / 53

页数：2

共 50 条

[21] Incidence of infusion-related reactions in patients receiving infliximab.
Buch, MH
Bryer, D
Fairclough, A
ReesEvans, B
Emery, P
ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S325 - S325
[22] The Presence of Anti-Rituximab Antibodies Predicts Infusion-Related Reactions in Patients with Systemic Lupus Erythematosus
Wincup, Chris
Menon, Madhvi
Smith, Edward
Isenberg, David A.
Jury, Elizabeth
Mauri, Claudia
ARTHRITIS & RHEUMATOLOGY, 2018, 70
[23] Standardized Titration Protocol Reduces the Incidence of Paclitaxel Infusion-Related Hypersensitivity Reactions
Sefah, Kofi
Kilowski, Karolina A.
Gifford, Sarah A.
Grove, Angela
Shaffer, Jon
Bryan, Baylee
Ahmad, Sarfraz
Holloway, Robert W.
JCO ONCOLOGY PRACTICE, 2023, 19 (12) : 1199 - +
[24] Management of infusion-related reactions (IRRs) in patients receiving amivantamab
Park, K.
Sabari, J. K.
Haura, E. B.
Shu, C. A.
Spira, A.
Salgia, R.
Reckamp, K. L.
Sanborn, R. E.
Govindan, R.
Bauml, J. M.
Curtin, J. C.
Xie, J.
Roshak, A.
Lorenzini, P.
Millington, D.
Thayu, M.
Knoblauch, R. E.
Cho, B. C.
ANNALS OF ONCOLOGY, 2021, 32 : S981 - S982
[25] Presence of anti-rituximab antibodies predicts infusion-related reactions in patients with systemic lupus erythematosus
Wincup, Chris
Menon, Madhvi
Smith, Edward
Schwartz, Ann
Isenberg, David
Jury, Elizabeth C.
Mauri, Claudia
ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 (08) : 1140 - +
[26] Patients with infusion-related reactions on fixed-dose rituximab treatment have higher body surface area than those without infusion-related reactions in adults with frequently relapsing minimal change nephrotic syndrome: a retrospective study
Nishiura, Hironobu
Takahashi, Masaya
Mori, Katsuhito
Sugimoto, Takashi
Emoto, Masanori
Nakamura, Yasutaka
JOURNAL OF PHARMACEUTICAL HEALTH CARE AND SCIENCES, 2024, 10 (01)
[27] Characteristics and predictors of infusion-related reactions to rituximab in patients with B-cell non-Hodgkin lymphoma
Faqeer, Nour
Alrabie, Rawaa
Al-Haddadin, Rand
Ma'koseh, Mohammad
JOURNAL OF CHEMOTHERAPY, 2024, 36 (04) : 291 - 298
[28] Analysis of Risk Factors for Infusion-Related Reactions Following Rituximab Administration in Patients with Desensitization before Renal Transplantation
Nishiura, Hironobu
Takahashi, Masaya
Iwai, Tomoaki
Uchida, Junji
Nakamura, Yasutaka
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2023, 46 (09) : 1332 - 1337
[29] Patients with infusion-related reactions on fixed-dose rituximab treatment have higher body surface area than those without infusion-related reactions in adults with frequently relapsing minimal change nephrotic syndrome: a retrospective study
Hironobu Nishiura
Masaya Takahashi
Katsuhito Mori
Takashi Sugimoto
Masanori Emoto
Yasutaka Nakamura
Journal of Pharmaceutical Health Care and Sciences, 10
[30] A novel rituximab administration protocol to minimize infusion-related adverse reactions in patients with B-cell lymphoma
Tsutsumi, Daisuke
Hayama, Tatsuya
Miura, Katsuhiro
Uchiike, Akihiro
Tsuboi, Shinya
Otsuka, Susumu
Hatta, Yoshihiro
Kishikawa, Yukinaga
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2022, 44 (02) : 366 - 373

← 1 2 3 4 5 →